This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

AKEEGA® (niraparib and abiraterone acetate)

Medical Information

AKEEGA - Administration via a Feeding Tube

Last Updated: 06/24/2024

Summary

  • Johnson & Johnson cannot recommend any practices, procedures, handling, or dosage and administration techniques that deviate from the approved product labeling.
  • AKEEGA is not commercially available as a solution or suspension.
  • Data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of crushing, splitting, or dispersion of AKEEGA tablets for administration, have not been published.
  • Data on the administration of AKEEGA tablets via a feeding tube (eg, nasogastric tube [NG-tube], gastric tube [G-tube], jejunal tube [J-tube]) have not been published.

CLINICAL DATA

No relevant clinical study information was identified for the administration of AKEEGA tablets via a feeding tube.

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 24 June 2024 did not identify any relevant citations pertaining to this topic in patients with prostate cancer.